CIK 0001516551
- Non-accelerated filer
- Smaller reporting company
Skye Bioscience, Inc.
Sign in to watch- Ticker
- SKYE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 450692882
- Phone
- +1 858-410-0266
- Business address
- 11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA, 92130
- Former names
- Emerald Bioscience, Inc., Nemus Bioscience, Inc., LOAD GUARD LOGISTICS, INC., LOAD GUARD TRANSPORTATION, INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $613,506
- in 6 filings
Net −$613,506. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-12-14 | Arsenault Kaitlyn Melanie Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +1,770,000 | 1,770,000 | ||
| 2021-12-14 | Ward Keith Wayne Director | Grant or award · Director Option Grant (Right to Buy) | +250,000 | 250,000 | ||
| 2021-10-04 | Arsenault Kaitlyn Melanie Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +1,600,000 | 2,000,000 | ||
| 2021-09-14 | DALESANDRO MARGARET Director | Grant or award · Director Stock Option (Right to Buy) | +150,000 | 400,000 | ||
| 2021-09-14 | HEPPELL JAMES L Director | Grant or award · Director Stock Option (Right to Buy) | +150,000 | 1,350,000 | ||
| 2021-09-14 | TYLE PRAVEEN Director | Grant or award · Director Stock Option (Right to Buy) | +25,000 | 275,000 | ||
| 2021-07-22 | TYLE PRAVEEN Director | Grant or award · Director Option Grant (Right to Buy) | +250,000 | 250,000 | ||
| 2020-08-07 | Emerald Health Sciences Inc. 10% owner | Sale | −2,566,666 | $0.10 | $257K | 123,923,501 |
| 2020-08-07 | DALESANDRO MARGARET Director | Grant or award · Director Option Grant (Right to Buy) | +250,000 | 250,000 | ||
| 2020-08-07 | Emerald Health Sciences Inc. 10% owner | Sale | −3,000,000 | $0.10 | $300K | 123,490,167 |
| 2020-08-07 | DHILLON PUNIT CEO | Purchase | +1,000,000 | $100,000.00 | $100.0B | 1,000,000 |
| 2020-08-07 | DHILLON PUNIT CEO | Grant or award · Employee Option Grant (Right to Buy) | +9,000,000 | 9,200,000 | ||
| 2020-08-07 | HEPPELL JAMES L Director | Purchase | +500,000 | $50,000.00 | $25.0B | 500,000 |
| 2020-08-07 | HEPPELL JAMES L Director | Grant or award · Director Option Grant (Right to Buy) | +1,000,000 | 1,200,000 | ||
| 2020-08-07 | KIM DENNIS D Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +4,000,000 | 4,736,541 | ||
| 2020-08-07 | Traistaru Elena CFO and Secretary | Grant or award · Consultant Option Grant (Right to Buy) | +1,000,000 | 1,000,000 | ||
| 2019-12-20 | Emerald Health Sciences Inc. 10% owner | Other acquisition | +40,800,000 | $4,080,000.00 | $166464.0B | 126,490,167 |
| 2019-12-20 | Emerald Health Sciences Inc. 10% owner | Other disposition · Warrant(Right to Buy) | −40,800,000 | $0.10 | $4.1M | 0 |
| 2019-12-20 | Emerald Health Sciences Inc. 10% owner | Other disposition · 7% Convertible Debt | −4,080,000 | $0.40 | $1.6M | 5,036,250 |
| 2019-08-21 | KIM DENNIS D Chief Medical Officer | Grant or award · Employee Stock Options (Right to Buy) | +736,541 | 736,541 |
Page 12 of 15 · 292 trades